We are live on ! Find out more
CLRBW

Cellectar Biosciences, Inc.
CLRBW

Delisted

CLRBW was delisted on the 20th of August, 2019.

Back to rankings

3 hedge funds and large institutions have $20K invested in Cellectar Biosciences, Inc. in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% less funds holding

Funds holding: 4 → 3 (-1)

79% less capital invested

Capital invested by funds: $95K → $20K (-$75K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$146

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$85K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$20K – – –
SM
2
Sabby Management
Florida
– -$85K -201,889 Closed
UBS Group
3
UBS Group
Switzerland
– +$146 +510 +1,275%

CLRBW Hedge Fund Activity: Q1 2017 in Review

3 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. (CLRBW) for Q1 2017, worth a combined $20K — down 79% from $95K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CLRBW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $146. The largest seller was Sabby Management, exiting entirely with an estimated $85K sold.

  • 3 institutional investors held Cellectar Biosciences, Inc. (CLRBW) as of Q1 2017, down from 4 in Q4 2016.
  • Funds reported $20K of Cellectar Biosciences, Inc. stock for Q1 2017, down 79% quarter-over-quarter.
  • 0 funds opened new Cellectar Biosciences, Inc. positions in Q1 2017 and 1 closed out, a net change of -1 holder.
  • The largest Cellectar Biosciences, Inc. buyer in Q1 2017 was UBS Group, an estimated $146 added.
  • The largest Cellectar Biosciences, Inc. seller in Q1 2017 was Sabby Management, an estimated $85K sold.

Based on aggregated 13F filings for Q1 2017.